COVID-19 vaccine effectiveness on variants of concern
(Randomized evidence)

Methods

Variants of concern

Description of primary studies

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
Alpha
Beta
Gamma
NCT04611802
Novavax
Dunkle L M, medRxiv, 2021
New

Full text
Commentary
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Healthy adults in 113 sites in the USA and 6 in Mexico N=29949
Some concerns
Details

Full description

Alpha
Delta
NCT04641481
Bharat Biotech
Ella R, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

BBV152

Placebo

RCT
Phase 3
Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India N=25778
Some concerns
Details

Full description

Alpha
NCT04400838
AstraZeneca + University of Oxford
Emary K, Lancet, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

MenACWY

RCT
Phase 2-3
Adults seronegative at baseline enrolled at 19 study sites in UK N=10673
Some concerns
Details

Full description

Alpha
Beta
Gamma
Delta
NCT04516746
AstraZeneca + University of Oxford
Falsey A, N Engl J Med, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 3
Adults (22% over 65 years) at high risk for exposure to SARS-CoV-2 and populations at increased risk for Covid-19 complications at 88 sites in USA, Chile, and Peru N=32451
Some concerns
Details

Full description

Alpha
NCT04583995; EudraCT 2020-004123-16
Novavax
Heath P, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK. N=15187
Some concerns
Details

Full description

Alpha
Gamma
NCT04652102; EudraCT 2020-003998-22
CureVac AG
Kremsner P, SSRN, 2021
HERALD

Full text
Commentary
Commentary
RNA based vaccine

CVnCoV

Placebo

RCT
Phase 2-3
Adults with no history of COVID-19 in 47 centers in Belgium, Germany, The Netherlands, Spain, Argentina, Colombia, Dominican Republic, Mexico, Panama and Peru N=39529
Some concerns
Details

Full description

Beta
NCT04444674
AstraZeneca + University of Oxford
Madhi S, N Engl J Med, 2021
COV005

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in 7 centres in South Africa N=2026
Some concerns
Details

Full description

Beta
Gamma
NCT04764422
The Government Pharmaceutical Organization (GPO); PATH; Dynavax
Pitisuttithum P, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

NDV-HXP-S 1mcg

NDV-HXP-S 1mcg + CpG1018

NDV-HXP-S 3mcg

NDV-HXP-S 3mcg + CpG1018

NDV-HXP-S 10mcg

Placebo

RCT
Phase 1
Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand N=210
Some concerns
Details

Full description

Beta
NCT04505722
Janssen Pharmaceutical Companies
Sadoff J, N Engl J Med, 2021
ENSEMBLE

Full text
Commentary
Non replicating viral vector

Ad26.COV2.S

Placebo

RCT
Phase 3
Adults >18 years of age at 213 centers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and USA N=44325
Some concerns
Details

Full description

Beta
NCT04533399; PACTR202009726132275
Novavax
Shinde V, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 2a/b
HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa N=4406
Some concerns
Details

Full description

Beta
NCT04762680
Sanofi Pasteur + GlaxoSmithKline
Sridhar S, medrxiv, 2021
New

Full text
Commentary
Commentary
Protein subunit

CoV2 preS dTM 15µg

CoV2 preS dTM 10µg

CoV2 preS dTM 5µg

RCT
Phase 2
Adults with and without prior SARS-CoV-2 infection and risk factors for severe disease at 20 centers in the USA and Honduras N=722
Low
Details

Full description

Beta
NCT04368728
Pfizer/BioNTech + Fosun Pharma
Thomas S, N Engl J Med, 2021

Full text
Commentary
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2-3
Children (>=12Y yo), adolescentes and adults, with no history or SARS-CoV 2 infection at 152 sites in Argentina, Brazil, Germany, South Africa, Turkey and USA N=44165
Some concerns
Details

Full description